Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest

• Asıl Yazarlar: Lisa Schaeffer (Yazar), Nesrine Ben-Anaya (Yazar), Christina Sorbe (Yazar), Stephan Jeff Rustenbach (Yazar), Ulrich Mrowietz (Yazar), Matthias Augustin (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

AbstractBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with pso...